Neoadjuvant Abemaciclib and Fulvestrant Facilitates High Complete Gross Resection Rate in Low-Grade Serous CancerJune 15th 2022
The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.
Radiotherapy Use in ATLAS Is Reflective of Current Guidance in High-Risk Localized Prostate CancerJune 14th 2022
Apalutamide plus androgen deprivation therapy and radiotherapy was evaluated in patients with high- and very high–risk localized or locally advanced prostate cancer, with RT schedules that are reflective of recommended practice guidelines.
Sotorasib Produces Encouraging Antitumor Activity in Heavily Pretreated KRAS G12C–Mutated Pancreatic CancerJune 14th 2022
Sotorasib demonstrated clinically meaningful activity and acceptable tolerability in heavily pretreated patients with KRAS G12C–mutated advanced pancreatic cancer, according to date from the single-arm, phase 1/2 CodeBreak 100 trial.
First-Line Toripalimab Plus Chemotherapy Elicits Survival Benefit in NSCLC Irrespective of PD-L1 StatusJune 9th 2022
Adding toripalimab to chemotherapy in the frontline setting demonstrated improved progression-free survival vs placebo plus chemotherapy in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.
Zanubrutinib Continues to Provide Clinically Meaningful Advantages Over Ibrutinib in Waldenström MacroglobulinemiaJune 9th 2022
Zanubrutinib continued to demonstrate a higher complete response or very good partial response rate and less off-target activity compared with ibrutinib in patients with MYD88-mutated Waldenström macroglobulinemia.
Updated RATIONALE-309 Data Support Use of Tislelizumab/Chemo in Frontline Recurrent/Metastatic Nasopharyngeal CancerJune 9th 2022
Tislelizumab plus chemotherapy continued to improve progression-free survival over chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated data from the RATIONALE-309 trial.
PSA Response Following Darolutamide Triplet Linked to OS Benefit in mHSPCJune 8th 2022
Treatment with darolutamide, androgen deprivation therapy, and docetaxel that elicited a PSA response was linked to improved overall survival in patients with metastatic hormone-sensitive prostate cancer.
Tucatinib Plus First-Line Maintenance Under Exploration in Metastatic HER2+ Breast CancerJune 8th 2022
Tucatinib plus first-line standard-of-care maintenance therapy with trastuzumab and pertuzumab is being investigated for its ability to improve progression-free survival and maintain health-related quality of life in patients with HER2-positive metastatic breast cancer.
Dostarlimab Demonstrates Promising Response Rates in Advanced, Recurrent Endometrial CancerJune 8th 2022
Single-agent dostarlimab generated durable antitumor activity in patients with advanced or recurrent endometrial cancer with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease.
Asciminib Represents New Standard of Care for Patients With CML in Chronic PhaseJune 7th 2022
Asciminib continued to demonstrate durable, major molecular responses as well as a tolerable safety profile vs bosutinib suggesting a long-term benefit in adult patients with chronic myelogenous leukemia in chronic phase who have been previously treated with 2 tyrosine kinase inhibitors.
Cobimetinib/Vemurafenib Combo Showcases Antitumor Activity in BRAF-Mutated Solid TumorsJune 7th 2022
A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.
Adagrasib Delivers Durable CNS-Specific Activity in KRAS G12C+ NSCLCJune 7th 2022
Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.
Afatinib Efficacy and Safety to Be Investigated in Metastatic Solid Tumors With NRG1 FusionsJune 7th 2022
Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.
Selinexor Demonstrates PFS Benefit in Advanced Endometrial Cancer, Including p53 Wild-Type Tumors
Selinexor generated a longer median progression-free survival compared with placebo in patients with advanced or recurrent endometrial cancer, including those with p53 wild-type tumors.
PDS0101 Shows Synergistic Activity With Pembrolizumab in HPV16+ Head and Neck Squamous Cell CarcinomaJune 7th 2022
The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.
Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma
The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.
Zanubrutinib Plus Obinutuzumab Elicits Improved Response Rates in Relapsed/Refractory Follicular LymphomaJune 7th 2022
The addition of zanubrutinib to obinutuzumab achieved an improved overall response rate, overall survival, and progression-free survival, compared with obinutuzumab alone, in patients with relapsed/refractory follicular lymphoma.
Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%June 7th 2022
Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.
Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion CancersJune 7th 2022
Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.
Panitumumab Plus Intensified Chemotherapy Fails to Improve Efficacy in mCRCJune 7th 2022
The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.
Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLCJune 7th 2022
Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.
Ribociclib Dose Reductions Do Not Affect Survival Outcomes in HR+/HER2- Advanced Breast CancerJune 7th 2022
Overall survival outcomes for patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib in the phase 3 MONALEESA-2 trial were comparable to those seen among patients who received the standard dose.
Sugemalimab and Chemotherapy Displays Significant OS Improvement in NSCLCJune 7th 2022
Sugemalimab plus chemotherapy improved overall survival (OS) vs placebo plus chemotherapy in patients with newly diagnosed metastatic non–small cell lung cancer, irrespective of PD-L1 expression or tumor histology.
Radiotherapy Unnecessary for Some Luminal A Breast Cancers
Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study.